New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
08:36 EDTRIGLRigel still poised to report good fostamatinib results, says Stifel Nicolaus
After Rigel Pharmaceuticals reported that its fostamatinib drug for rheumatoid arthritis.had failed to demonstrate non-inferiority versus a competing drug, Stifel reports that the results don't alter its forecast for fostamatinib's Phae III trials. The firm thinks the decline in Rigel's stock following the results were overdone and it maintains a Buy rating.
News For RIGL From The Last 14 Days
Check below for free stories on RIGL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for RIGL

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use